| NCT ID | NCT06469801 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Children's Mercy Hospital Kansas City |
| Condition | Acute Brain Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-07-23 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-07-23 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective is to characterize the prevalence and type of ABI following cannulation for pediatric patients who require ECMO support. The secondary objective is to describe the time course and rates of ABI using ultralow-field bedside MRI relative to both duration of ECMO support and clinical imaging obtained in routine care of pediatric ECMO patients.
Eligibility Criteria
Inclusion Criteria * Participants that will be or are admitted to the Pediatric Intensive Care Unit, Cardiac Intensive Care Unit, or the Neonatal Intensive Care Unit * Ages 0-17 years * Participants that are at high risk for undergoing ECMO or are currently undergoing venovenous or venoarterial ECMO • High risk participants include, but are not limited to: * Undergoing cardiac surgery * Congenital heart disease * Congenital diaphragmatic hernia * Refractory hypoxemic and/or hypercarbic respiratory failure * Vasoactive-refractory shock Exclusion Criteria * Pregnancy * Active implants such as: * Pacemaker * Implanted defibrillator * Implanted insulin pump * Deep brain stimulator * Vagus nerve stimulator * Cochlear implant * Programmable shunt * MRI incompatible surgical hardware (e.g., staples, screws, etc.) * Metal-containing tattoos or permanent make-up on head or neck * Suspected metal in eye, e.g., * Former or current welders, metal workers, or individuals with a metal injury * Metal shrapnel * Passive implants are considered MRI-conditional
Contact & Investigator
Jessica Wallisch, MD
PRINCIPAL INVESTIGATOR
Children's Mercy Kansas City
Frequently Asked Questions
Who can join the NCT06469801 clinical trial?
This trial is open to participants of all sexes, aged 0 Days or older, up to 17 Years, studying Acute Brain Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06469801 currently recruiting?
Yes, NCT06469801 is actively recruiting participants. Contact the research team at mesien@cmh.edu for enrollment information.
Where is the NCT06469801 trial being conducted?
This trial is being conducted at Kansas City, United States.
Who is sponsoring the NCT06469801 clinical trial?
NCT06469801 is sponsored by Children's Mercy Hospital Kansas City. The principal investigator is Jessica Wallisch, MD at Children's Mercy Kansas City. The trial plans to enroll 30 participants.